Clotting Propensity of Surface-Treated Membranes in a Hemodialysis Set-up That Avoids Systemic Anticoagulation

Hideki Kawanishi, Masahide Koremoto, Casper F M Franssen*, Marco van Londen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)
26 Downloads (Pure)

Abstract

The development of biocompatible membranes, aiming to limit the inflammatory response, oxidative stress, and coagulability during hemodialysis, has been an important step in reducing dialysis-related adverse outcomes. This includes a reduction in the risk of clotting of the extracorporeal circuit, thus enabling hemodialysis with a reduced dose or even without systemic anticoagulant drugs in patients with an increased bleeding risk. In this article, we summarize the in vitro research and clinical evidence on the antithrombotic properties of vitamin E- and heparin-coated membranes.

Original languageEnglish
Article number151482
Number of pages10
JournalSeminars in Nephrology
DOIs
Publication statusAccepted/In press - 2024

Keywords

  • Anticoagulation
  • dialyzer
  • hemodialysis
  • heparin-coated
  • membrane
  • vitamin E-coated

Fingerprint

Dive into the research topics of 'Clotting Propensity of Surface-Treated Membranes in a Hemodialysis Set-up That Avoids Systemic Anticoagulation'. Together they form a unique fingerprint.

Cite this